The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging ... to make sure the immunotherapy spares healthy blood cells and reduces treatment side ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality ...

A 77-year-old woman was admitted to Matsunami General Hospital (Gifu, Japan) with anaemia and thrombocytopenia. Clinical ...

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS ...

when used as first-line treatment of adult patients with IPSS-R MDS requiring RBC transfusions, and who were erythropoiesis stimulating agent (ESA) naïve. The results were based on pre-specified ...

Allogeneic stem cell transplant (allo-HSCT) is part of the standard treatment paradigm for acute leukemia and myelodysplastic syndrome (MDS). But like most therapies for hematologic malignancies ...

Geron filed imetelstat with the FDA last August as a treatment for transfusion-dependent anaemia in lower-risk MDS patients and is waiting for the outcome of the agency’s review, expected in mid ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...